Laidlaw acts as Sole-Book Runner on the $3,500,000 BioSig Technologies’ Follow-On Transaction.
Laidlaw Capital Markets is pleased to have acted as Sole-Book Runner on the $3,500,000 Common Stock transaction for BioSig Technologies (BSGM). Read Article
Laidlaw served as Co-Manager on the $115,000,000 Offering for Affimed (AFMD)
Laidlaw Capital Markets is pleased to have Co-Managed Affimed’s $115,000,000 financing alongside Jefferies, SVB Leerink, and Credit Suisse. See full Press Release on Affimed Website
Laidlaw served as Sole Book-Runner on the $14,375,000 Offering for Evoke Pharma (EVOK)
Laidlaw Capital Markets is pleased to have acted as the Sole Book-Runner on the $14,375,000 Follow-On Offering for Evoke Pharma (EVOK). Evoke has been a partner for years now and we are excited for their Read More...
Laidlaw served as Financial Advisor on the $20,000,000 Offering for Delcath Systems (DCTH)
Laidlaw Capital Markets is pleased to have served as a Financial Advisor to Delcath Systems on their $20,000,000 Follow-on Offering alongside Canaccord Genuity and Roth Capital
Voltron Therapeutics, Inc. Announces Positive Data from Animal Testing of Self-Assembling Vaccine in the Fight Against COVID-19
From globenewswire.com: Voltron Therapeutics, Inc. today announced positive data from its second set of preclinical animal testing of its HaloVax™ Self-Assembling Vaccine (SAV) against COVID-19. This study investigated an updated construct, based on initial testing Read More...
Laidlaw Capital Markets is pleased to have acted as Co-Manager on the $25,000,000 Follow-On Offering for iCAD Inc.
The Team at Laidlaw Capital Markets is pleased to have acted as the Co-Manager on the $25,000,000 Follow-On Offering for iCAD, Inc. (ICAD). iCAD has been a partner for years now and we are excited Read More...
Stay In Touch